Pharmacognosy Magazine

: 2021  |  Volume : 17  |  Issue : 75  |  Page : 623--629

Antiosteoporotic effect of fisetin in an estrogen deficient model of osteoporosis

Cong Xu1, Fei Liu2, Yu Yang3, Feng Yuan4, Bo Zhou5, Yadong Liu6 
1 Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
2 Department of Orthopaedics, The Third College of Clinical Medical Sciences, China Three Gorges University, Yichang; Department of Orthopaedics, Gezhouba Central Hospital, Yichang, Hubei, China
3 Department of Minimally Invasive Spine Surgery, Yu Lin Orthopaedic Hospital of Chinese and Western Medicine, Yulin, Guangxi, China
4 Sport Medicine, Shanghai Sixth People's Hospital East Affiliated to Shanghai Univesity of Medicine and Health Sciences, Shanghai, China
5 Department of Orthopedics, Yixing People's Hospital, Yixing, Jiangsu, China
6 Department of Microsurgery of Hand and Foot Ankle, Affliated Dongfeng Hospital, Hubei University of Medicine (Sinopharm Dongfeng General Hospital), Shiyan, Hubei, China

Correspondence Address:

Background: Osteoporosis is a serious health problem, especially in the geriatric populations. World widely, it exaggerated the 8.9 million people every year roughly. In the current analysis, we assessed the antiosteoporotic effect of fisetin on the osteoporosis model ovariectomized (OVX) rat. Materials and Methods: Fisetin was orally administrated at dose of 5, 10, and 20 mg/kg to OVX rats for 16 weeks. Different biochemical parameters such as alkaline phosphatase (ALP), osteocalcin, phosphorus, calcium, and urinary deoxypyridinoline were also projected. 3-point bending test, bone mineral density (BMD), and histomorphometric feature of the femoral bone were also examined. Results: Fisetin significantly decreased the body weight and increased the uterine weight. A significant decrease detected in the level of ALP, serum calcium, while the level of the serum phosphorus, OC augmented after fisetin administration. Fisetin significantly (P < 0.001) reduced the homocysteine, C-terminal crosslinked telopeptides of collagen type I, interferon gamma, and increased the level of OC. Fisetin also augmented the level of BMD. Fisetin considerably increased the energy, maximum load, maximum stress, young modulus, and stiffness. The level of cytokines such as tumor necrosis factor-α, interleukin (IL)-6, and IL-1 β also diminished pointedly after fisetin treatment. Fisetin significantly boosted the estrogen (E2) level and reduced the level of follicle-stimulating hormone and luteinizing hormone. Conclusion: Communally, we can accomplish that fisetin exhibited the better protection against osteoporosis through augmenting the bone density and bone mineral content in addition to biomechanical parameters.

How to cite this article:
Xu C, Liu F, Yang Y, Yuan F, Zhou B, Liu Y. Antiosteoporotic effect of fisetin in an estrogen deficient model of osteoporosis.Phcog Mag 2021;17:623-629

How to cite this URL:
Xu C, Liu F, Yang Y, Yuan F, Zhou B, Liu Y. Antiosteoporotic effect of fisetin in an estrogen deficient model of osteoporosis. Phcog Mag [serial online] 2021 [cited 2022 Dec 3 ];17:623-629
Available from:;year=2021;volume=17;issue=75;spage=623;epage=629;aulast=Xu;type=0